Ultima Ipamorelin: Compound Profile
Ipamorelin is a pentapeptide growth hormone secretagogue belonging to the ghrelin receptor agonist class. This selective compound demonstrates specificity for growth hormone release pathways without significantly affecting cortisol or prolactin levels in preclinical models. Researchers at Stroid UK Shop utilise this peptide to investigate selective hormone axis modulation and comparative efficacy studies against traditional GHRH analogues. The compound’s molecular specificity makes it valuable for examining discrete endocrine signalling pathways in laboratory settings.
Laboratory Applications
Research teams investigate Ipamorelin’s role as a selective ghrelin receptor agonist in growth hormone physiology studies. The peptide’s advancement through Phase II clinical trials for post-surgical ileus provides validated research frameworks for examining gastrointestinal motility mechanisms. Comparative analyses with other peptides reveal distinct selectivity profiles useful for hormone receptor characterisation studies. Metabolic research applications examine the compound’s effects on IGF-1 expression and downstream anabolic signalling cascades in cellular models.
Technical Specifications
| CAS Number | 170851-70-4 |
|---|---|
| Molecular Weight | 711.85 g/mol |
| Chemical Class | Pentapeptide growth hormone secretagogue |
| Purity Grade | Research standard |
| Storage Requirements | Lyophilised powder: -20°C |
| Supplier | Ultima Pharmaceuticals USA |
Research protocols frequently compare Ipamorelin selectivity against traditional SARMs compounds to establish distinct receptor binding profiles. The compound’s ghrelin mimetic properties provide researchers with tools for examining appetite regulation mechanisms and energy homeostasis pathways. Studies investigating the peptide alongside Ipamorelin research materials demonstrate its utility in comprehensive endocrine research programmes examining growth factor regulation and metabolic control mechanisms.
Compliance Statement
This Ipamorelin product is manufactured by Ultima Pharmaceuticals exclusively for in-vitro research applications. The material is not intended for human consumption, clinical use, or any application outside controlled laboratory environments. Researchers must ensure compliance with institutional guidelines and local regulations governing peptide research materials before conducting any experimental procedures.
